Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CNSP NASDAQ:GRML NASDAQ:KYNB NASDAQ:PTPI On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCNSPCNS Pharmaceuticals$4.68-3.7%$5.08$1.90▼$11.16$6.83M3.06689,894 shs3,669 shsGRMLGreenland Mines Ltd. Common Stock$0.18+0.9%$0.32$0.18▼$1.38$25.11M7.053.48 million shs3.44 million shsKYNBKyntra Bio$7.21-1.5%$7.04$6.32▼$12.60$29.20M0.9625,233 shs7,346 shsPTPIPetros Pharmaceuticals$0.00+9.5%$0.01$0.00▼$0.03$143K1.86107,635 shs15,444 shs10 Best Stocks to Own - Summer 2026Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCNSPCNS Pharmaceuticals-4.52%-4.89%-0.61%+76.73%-53.74%GRMLGreenland Mines Ltd. Common Stock-14.24%-24.55%-38.53%-65.64%-85.59%KYNBKyntra Bio-0.27%-2.92%+2.66%+2.81%+731,999,900.00%PTPIPetros Pharmaceuticals-16.00%-10.64%-40.00%-30.00%-84.73%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCNSPCNS Pharmaceuticals$4.68-3.7%$5.08$1.90▼$11.16$6.83M3.06689,894 shs3,669 shsGRMLGreenland Mines Ltd. Common Stock$0.18+0.9%$0.32$0.18▼$1.38$25.11M7.053.48 million shs3.44 million shsKYNBKyntra Bio$7.21-1.5%$7.04$6.32▼$12.60$29.20M0.9625,233 shs7,346 shsPTPIPetros Pharmaceuticals$0.00+9.5%$0.01$0.00▼$0.03$143K1.86107,635 shs15,444 shs10 Best Stocks to Own - Summer 2026Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCNSPCNS Pharmaceuticals-4.52%-4.89%-0.61%+76.73%-53.74%GRMLGreenland Mines Ltd. Common Stock-14.24%-24.55%-38.53%-65.64%-85.59%KYNBKyntra Bio-0.27%-2.92%+2.66%+2.81%+731,999,900.00%PTPIPetros Pharmaceuticals-16.00%-10.64%-40.00%-30.00%-84.73%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCNSPCNS Pharmaceuticals 2.00Hold$20.00327.35% UpsideGRMLGreenland Mines Ltd. Common Stock 1.00SellN/AN/AKYNBKyntra Bio 2.60Moderate Buy$32.50350.76% UpsidePTPIPetros Pharmaceuticals 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest CNSP, PTPI, KYNB, and GRML Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/6/2026KYNBKyntra Bio OppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$35.006/29/2026GRMLGreenland Mines Ltd. Common Stock Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)6/16/2026KYNBKyntra Bio Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D)6/9/2026GRMLGreenland Mines Ltd. Common Stock Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)6/9/2026KYNBKyntra Bio Rodman & RenshawSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$30.004/22/2026GRMLGreenland Mines Ltd. Common Stock Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)4/20/2026CNSPCNS Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)(Data available from 7/15/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCNSPCNS PharmaceuticalsN/AN/AN/AN/A$7.29 per shareN/AGRMLGreenland Mines Ltd. Common StockN/AN/AN/AN/A$0.13 per shareN/AKYNBKyntra Bio$6.44M4.53N/AN/A($4.20) per share-1.72PTPIPetros Pharmaceuticals$5.11M0.03N/AN/A$4.04 per share0.00Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCNSPCNS Pharmaceuticals-$15.85M-$29.63N/AN/AN/AN/A-238.68%-166.30%8/17/2026 (Estimated)GRMLGreenland Mines Ltd. Common Stock-$10.55M-$0.32N/AN/AN/AN/A-109.40%-98.80%N/AKYNBKyntra Bio$183.45M$40.460.18N/AN/A2,199.13%N/A-36.71%N/APTPIPetros Pharmaceuticals-$8.16M-$1.64N/AN/AN/AN/A-78.22%-23.50%N/ALatest CNSP, PTPI, KYNB, and GRML EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/20/2026Q1 2026GRMLGreenland Mines Ltd. Common StockN/A-$0.15N/A-$0.15N/AN/A5/14/2026Q1 2026CNSPCNS Pharmaceuticals-$8.82-$7.30+$1.52-$7.30N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthCNSPCNS PharmaceuticalsN/AN/AN/AN/AN/AGRMLGreenland Mines Ltd. Common StockN/AN/AN/AN/AN/AKYNBKyntra BioN/AN/AN/AN/AN/APTPIPetros PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCNSPCNS PharmaceuticalsN/A0.890.89GRMLGreenland Mines Ltd. Common StockN/A19.7319.73KYNBKyntra BioN/A3.613.48PTPIPetros Pharmaceuticals1.580.850.74Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCNSPCNS Pharmaceuticals14.02%GRMLGreenland Mines Ltd. Common Stock20.07%KYNBKyntra Bio72.71%PTPIPetros Pharmaceuticals12.34%Insider OwnershipCompanyInsider OwnershipCNSPCNS Pharmaceuticals0.01%GRMLGreenland Mines Ltd. Common Stock11.30%KYNBKyntra Bio4.15%PTPIPetros Pharmaceuticals12.25%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCNSPCNS Pharmaceuticals51.46 million1.46 millionNot OptionableGRMLGreenland Mines Ltd. Common Stock5138.13 million122.52 millionN/AKYNBKyntra Bio5704.05 million3.88 millionN/APTPIPetros Pharmaceuticals2031.16 million9.93 millionNot OptionableCNSP, PTPI, KYNB, and GRML HeadlinesRecent News About These CompaniesPetros Pharmaceuticals Delays Annual 10-K FilingMarch 31, 2026 | tipranks.comPetros Pharmaceuticals grants significant RSUs to key leadersJanuary 3, 2026 | msn.comPetros Pharmaceuticals to be Delisted from NasdaqNovember 7, 2025 | msn.comPetros Pharmaceuticals Inc (PTPI) - Investing.comSeptember 6, 2025 | investing.comPetros Pharmaceuticals, Inc.: Petros Pharmaceuticals Announces Deconsolidation of Metuchen Pharmaceuticals Subsidiary, Strengthening its Balance Sheet and Improving the Company ...June 26, 2025 | finanznachrichten.dePetros Pharmaceuticals Announces Deconsolidation of Metuchen Pharmaceuticals Subsidiary, Strengthening its Balance Sheet and Improving the Company's Equity Position | MorningstarJune 26, 2025 | morningstar.comMPetros Pharmaceuticals to deconsolidate subsidiary to improve financesJune 26, 2025 | investing.comPetros Pharmaceuticals, Inc. (PTPI) - Yahoo FinanceJune 26, 2025 | finance.yahoo.comPetros Pharmaceuticals Inc News (PTPI) - Investing.comJune 26, 2025 | investing.comPetros Pharmaceuticals Announces Deconsolidation of Metuchen Pharmaceuticals Subsidiary, Strengthening its Balance Sheet and Improving the Company's Equity PositionJune 25, 2025 | accessnewswire.comAPetros Pharmaceuticals to appeal Nasdaq delisting decisionMay 23, 2025 | uk.investing.comPetros Pharmaceuticals Announces Transition from NASDAQ to OTC MarketsMay 21, 2025 | accessnewswire.comAPetros Pharmaceuticals, Inc.: Petros Pharmaceuticals Partners with Innolitics, a Leading Software-as-a-Medical-Device DeveloperMay 20, 2025 | finanznachrichten.dePetros Pharmaceuticals Partners with Innolitics, a Leading Software-as-a-Medical-Device DeveloperMay 20, 2025 | accessnewswire.comAPetros Pharmaceuticals Strengthens Partnership with Market Leading Big Data Provider Implementing Key Enhancements to its AI PlatformMay 6, 2025 | accessnewswire.comAPetros Proprietary Technology Platform Aligns with April 15, 2025 President Trump Executive Order Advancing Rx-to-OTC Reclassification ReformsApril 29, 2025 | accessnewswire.comAPetros Pharmaceuticals, Inc.: Petros Pharmaceuticals to Partner with Renowned Big Data Provider to Enable Rx-to-OTC Switch Across Multiple IndicationsMarch 20, 2025 | finanznachrichten.dePetros Pharmaceuticals enters collaboration with big data, analytics firmMarch 20, 2025 | msn.comPetros Pharmaceuticals to Partner with Renowned Big Data Provider to Enable Rx-to-OTC Switch Across Multiple IndicationsMarch 20, 2025 | accessnewswire.comAPetros Pharmaceuticals, Inc.: Petros Pharmaceuticals' Proprietary Technology Demonstrates Positive Data in Pivotal StudyFebruary 27, 2025 | finanznachrichten.deNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCNSP, PTPI, KYNB, and GRML Company DescriptionsCNS Pharmaceuticals NASDAQ:CNSP$4.68 -0.18 (-3.70%) Closing price 03:58 PM EasternExtended Trading$4.70 +0.03 (+0.53%) As of 04:37 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors. The company's lead drug candidate is Berubicin, which completed Phase I clinical trial that is used for the treatment of glioblastoma multiforme. It has license agreements with Houston Pharmaceuticals, Inc., Reata Pharmaceuticals, Inc., Pomeranian Medical University, and The University of Texas M.D. Anderson Cancer Center; and a development agreement with WPD Pharmaceuticals Inc. The company was incorporated in 2017 and is based in Houston, Texas.Greenland Mines Ltd. Common Stock NASDAQ:GRML$0.18 +0.00 (+0.94%) As of 04:00 PM EasternGreenland Mines Ltd develops essential medicines for the treatment of chronic diseases - cancer, cardiovascular, and neurodegenerative disorders. The Company operates as a single reporting segment focused on developing essential medicines for these chronic diseases. The Company has acquired two licensed platforms: a generic drug portfolio and a biosimilar biologics platform that uses biologic therapies to treat cancer, and proprietary patented technologies involving melanocortin receptor-binding molecules and a gene therapy platform that introduces a therapeutic protein called Klotho inside the body to treat neurodegenerative diseases.Kyntra Bio NASDAQ:KYNB$7.21 -0.11 (-1.50%) Closing price 04:00 PM EasternExtended Trading$7.26 +0.05 (+0.76%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States, Europe, China, and Japan; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes. It is also developing Pamrevlumab, a human monoclonal antibody that inhibits the activity of connective tissue growth factor that is in Phase III clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, liver fibrosis, and diabetic kidney disease, as well as Phase III trial for the treatment of Duchenne muscular dystrophy. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.Petros Pharmaceuticals NASDAQ:PTPI$0.0046 +0.00 (+9.52%) As of 12:10 PM EasternPetros Pharmaceuticals, Inc., a pharmaceutical company, focuses on men's health therapeutics in the United States and internationally. It operates through two segments, Prescription Medications and Medical Devices. The company engages in the commercialization and development of Stendra, an PDE-5 inhibitor prescription medication for the treatment of erectile dysfunction (ED). It also develops and commercializes H100, a novel and patented topical formulation candidate for the treatment of acute Peyronie's disease. The company offers men's health products, including vacuum erection devices, penile injections, PreBoost, VenoSeal, and urinary tract infection tests for the treatment of erectile dysfunction. Petros Pharmaceuticals, Inc. is based in New York, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Why Johnson & Johnson’s Earnings Dip Looks Like a Buying Opportunity Apple’s AI Toll Booth Thesis Faces Its Biggest Test Yet Before Earnings Why ASML’s AI Monopoly Is Still Getting Stronger Alphabet’s AI Spending Question Looms Over Q2 Earnings CPI Comes In Cool: Why It Could Revive These 3 Rate-Sensitive Stocks 2 Quantum Stocks That Could Challenge IonQ’s Leadership 3 Small-Cap Stocks Trading Under $10 With Room to Run Plot Twist: 12 States Could Stall the Paramount-Warner Bros. Discovery Mega-Merger Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
